An­a­lysts see promise in Fi­bro­Gen's ear­ly Duchenne study — now they want to see a piv­otal tri­al

Apart from Pfiz­er $PFE, Fi­bro­Gen $FGEN on Fri­day al­so pre­sent­ed ear­ly da­ta on its drug for Duchenne mus­cu­lar dy­s­tro­phy.

The drug, pam­revlum­ab, is a mon­o­clon­al an­ti­body to con­nec­tive tis­sue growth fac­tor (CT­GF) cur­rent­ly un­der de­vel­op­ment as a treat­ment for non-am­bu­la­to­ry DMD pa­tients, id­io­path­ic pul­monary fi­bro­sis and lo­cal­ly ad­vanced pan­cre­at­ic can­cer. On Fri­day, the San Fran­cis­co-based drug de­vel­op­er un­veiled ear­ly da­ta from a small, sin­gle arm study at the Par­ent Project Mus­cu­lar Dy­s­tro­phy con­fer­ence in Or­lan­do, Flori­da.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER